CG OncologyCGON
CGON
About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees: 113
0
Funds holding %
of 7,311 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
79% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 34
34% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $859K
13% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 24
4.46% more ownership
Funds ownership: 88.38% [Q4 2024] → 92.84% (+4.46%) [Q1 2025]
1% more funds holding
Funds holding: 140 [Q4 2024] → 142 (+2) [Q1 2025]
8% less capital invested
Capital invested by funds: $1.9B [Q4 2024] → $1.74B (-$160M) [Q1 2025]
17% less funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 10 (-2) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
13%
downside
Avg. target
$56
114%
upside
High target
$75
185%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Morgan Stanley Jeffrey Hung | 113%upside $56 | Overweight Maintained | 17 Jun 2025 |
JP Morgan Brian Cheng | 56%upside $41 | Overweight Initiated | 2 May 2025 |
RBC Capital Gregory Renza | 158%upside $68 | Outperform Maintained | 29 Apr 2025 |
Cantor Fitzgerald Josh Schimmer | 185%upside $75 | Overweight Reiterated | 28 Apr 2025 |
HC Wainwright & Co. Andres Maldonado | 185%upside $75 | Buy Reiterated | 28 Apr 2025 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash position, providing a multi-year runway and reducing near-term dilution risk as it approaches potential commercialization. Key risk remains the lack of randomized data for FDA approval, but I view the likelihood of approval as high given the compelling clinical results.
Neutral
GlobeNewsWire
1 month ago
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
Positive
Zacks Investment Research
1 month ago
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Negative
Zacks Investment Research
1 month ago
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.
Negative
Zacks Investment Research
2 months ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
2 months ago
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Benzinga
2 months ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
Positive
Investors Business Daily
2 months ago
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.
Neutral
GlobeNewsWire
2 months ago
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
Charts implemented using Lightweight Charts™